Ten million doses expected by end of Q3
Johnson & Johnson, who has been making production headlines in the US, recently revealed that Health Canada has granted an interim order (IO) authorization for its single-shot Covid-19 vaccine, developed by J&J's Janssen Pharmaceutical Companies unit, to prevent Covid-19 in people 18 years of age and older.
This decision was based on scientific evidence, including data from the Phase III ENSEMBLE study that demonstrated the vaccine was 85% effective in preventing severe disease, and exhibited protection against Covid-19 related hospitalization and death, beginning 28 days after vaccination.
J&J envisions fulfilling the 10 million doses included in the advance purchase agreement with the government of Canada by the end of Q3.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.